FDA Approval Activities for this Drug
Arimidex (anastrozole) Tablets, AstraZeneca NDA 20-541/S10 9/5/02 9/11/02 9/5/02 7/8/03
Arimidex (anastrozole) Tablets, AstraZeneca NDA 20-541/S-005, S-009 10/7/02 10/11/01
Arimidex (anastrozole) Tablets, AstraZeneca NDA 20-541/S-006 9/1/00 9/21/00 7/12/01 7/12/01
Arimidex Indication: for the first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. ARIMIDEX 7 (anastrozole) Tablets, AstraZeneca, Labeling Revision | ARIMIDEX (anastrozole) Tablets, AstraZeneca Pharma, Accelerated Approval | Anastrozole Tablets, Synthon Pharma, Tentative Approval | Anastrozole Tablets, Roxane Labs, Tentative Approval | Anastrozole Tablets, TEVA Pharma, Tentative Approval | Anastrazole Tablets, Watson Labs, Tentative Approval | Anastrozole Tablets, Zydus Pharma, Tentative Approval | Anastrozone (anastrozole) Tablets, Sandoz, Inc., Tentative Approval | Anastrozole Tablets, Natco Pharma Ltd., Tentative Approval | Anastrozole Tablets, Stason Pharmaceuticals, Inc., Tentative Approval | Arimidex (anastrozole) Tablets, AstraZeneca Pharmaceutical, LP, Labeling Revision | Arimidex (anastrozole) Tablets, AstraZeneca, Approval | Arimidex (anastrozole) Tablets, AstraZeneca, Labeling Revision